drugset / Trial / NCT05226533

Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.

NCT05226533

Phase 2 Terminated 1 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Safety and efficacy of DWRX2003 combination with Remdesivir in moderate to severe COVID-19 patients will be confirmed.

Timeline

Start
2022-03-31
Primary completion
2022-12-16
Completion
2022-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Niclosamide Unknown 432 mg Other
Subject Niclosamide Unknown 960 mg Other

Indications